Related Experiment Video
Updated: Jan 8, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies
Chiara M S Herzog1,2, Jesse R Poganik3, Nicola Boekstein4
1Department of Twin Research and Genetic Epidemiology, School of Life Course and Population Sciences, Faculty of Medicine and Life Sciences, King's College London, London, UK.
Abstract:
Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology companies (LBCs) continue to plan and launch innovative clinical trials, standard practices in collecting data and applying biomarkers of aging will allow the field to support parallel and ongoing validation and benchmarking efforts for aging biomarkers. Moreover, defining best practices will ensure future reuse of valuable clinical data through pre-competitive alignment on shared tools. Here, we propose recommendations for such collections. We believe that wide adoption of these recommendations will allow LBCs to produce and leverage the highest quality data from their clinical trials, while also benefiting the geroscience field more broadly with minimal additional effort.
More Related Videos
08:01Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Longitudinal Research
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials
There are four phases in a clinical trial. A phase one...
Longitudinal Studies
Clinical Trials: Overview
Bioequivalence studies: Biowaivers